Second-generation antipsychotics: reviewing the cost–effectiveness component of the CATIE trial

References

• Rosack J. Drug firms vie to develop more effective antipsychotics. Psychiatr. News41, 25–29 (2006).
   Google Scholar
• Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch. Gen. Psychiatry60, 553–564 (2003).
   PubMed Web of Science ®Google Scholar
• Tamminga C. Clinical course and cellular pathology of tardive dyskinesia. In: Neuropsychopharmacology: The Fifth Generation of Progress. Davis KL, Charney DS, Coyle JT, Nemeroff C (Eds). Lippincott Williams & Wilkins, Baltimore, MD, USA (2002).
   Google Scholar
• Tarsy D. Baldessarini RJ. Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov. Disord.21(5), 589–598 (2006).
   PubMed Web of Science ®Google Scholar
• Rosenheck RA, Perlick D, Bingham S et al.; Department of Veterans Affairs Cooperative Study Group on the Cost–effectiveness of Olanzapine. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia. J. Am. Med. Assoc.290, 2693–2702 (2003).
   PubMed Web of Science ®Google Scholar
• Jones PB, Barnes TRE, Davies L et al. Randomized controlled trial of effect on quality of life of second generation versus first generation antipsychotic drugs in schizophrenia – CUtLASS1. Arch. Gen. Psychiatry63(10), 1079–1087 (2006).
   PubMed Web of Science ®Google Scholar
• Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet361, 1581–1589 (2003).
   PubMed Web of Science ®Google Scholar
• Hugenholtz GWK, Heerdink ER, Stolker JJ, Welmoed EEM, Egberts ACG, Nolen WA. Haloperidol dose when used as active comparitor in randomized controlled trials with atypical antipsychotics in schizophrenia: comparison with officially recommended doses. J. Clin. Psychiatry67(6), 897–903 (2006).
   Web of Science ®Google Scholar
• Geddes, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Br. Med. J.321, 1371–1376 (2000).
   Google Scholar
• Rosenheck RA. Efficacy vs. effectiveness of second generation antipsychotics: haloperidol without prophylactic anticholinergics as a comparitor. Psychiatr. Serv.56, 85–92 (2005).
   Google Scholar
• Carpenter WT and Gold JM Another view of therapy for cognition in schizophrenia. Biol. Psychiatry51(12), 969–971 (2002).
   PubMed Web of Science ®Google Scholar
• Hamilton SH, Revicki DA, Edgell ET, Genduso LA, Tollefson G. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia – results from a randomized clinical trial. Pharmacoeconomics15(5), 469–480 (1999).
   PubMed Web of Science ®Google Scholar
• Duggan M. Do new prescription drugs pay for themselves? The case of second-generation antipsychotics. J. Health Econ.24(1), 1–31 (2005).
   PubMed Web of Science ®Google Scholar
• American Diabetes Association (ADA), American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care27, 596–601 (2004).
   PubMed Web of Science ®Google Scholar
• Leslie D, Rosenheck RA. Pharmacotherapy and healthcare costs among patients with schizophrenia and newly diagnosed diabetes. Psychiatr. Serv.56(7), 803–810 (2005).
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup S, McEvoy J et al.; for the CATIE Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: primary efficacy and safety outcomes of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial. N. Engl. J. Med.353(12), 1209–1223 (2005).
   PubMed Web of Science ®Google Scholar
• Rosenheck RA, Leslie D, Sindelar J et al. Cost–effectiveness of second generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am. J. Psychiatry163(12), 2080–2089 (2006).
   PubMed Web of Science ®Google Scholar
• Lenert L, Sturley AP, Rapaport MH, Chavez S, Mohr P, Rupnow M. Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative syndrome scale scores. Schizophr. Res.71, 155–165 (2004).
   PubMed Web of Science ®Google Scholar
• Tollefson GD, Beasley CM Jr, Tran PV et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am. J. Psychiatry154, 457–465 (1997).
   PubMed Web of Science ®Google Scholar
• Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am. J. Psychiatry151, 825–35 (1994).
   PubMed Web of Science ®Google Scholar
• Breier A, Berg PH, Thakore JH et al. Olanzapine versus ziprasidone: results of a 28-week double blind study in patients with schizophrenia. Am. J. Psychiatry162(10), 1879–1887 (2005).
   PubMed Web of Science ®Google Scholar
• Meltzer HY and Bobo WV. Interpreting the efficacy findings in the CATIE study: what clinicians should know. CNS Spectr.11(7 Suppl. 7), 14–24 (2006).
   PubMedGoogle Scholar
• Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N. Engl. J. Med.346, 16–22 (2002).
   PubMed Web of Science ®Google Scholar
• Rubin DB. Multiple imputation after 18+ years. J. Am. Statist. Asso.91, 473–489 (1996).
   Web of Science ®Google Scholar
• Freedman R, Carpenter WT, Davis JM, Goldman HH, Tamminga C, Thomas M. The cost of drugs for schizophrenia. Am. J. Psychiatry163(12), 2029–2031 (2006).
   Google Scholar
• Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am. J. Psychiatry.161(3), 414–425 (2004).
   PubMed Web of Science ®Google Scholar
• Beasley CM, Dellva MA, Tamura RN et al. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br. J. Psychiatry174, 23–30 (1999).
   PubMed Web of Science ®Google Scholar
• Halliday J, Farrington S, Macdonald S, MacEwan T, Sharkey V, McCreadie R. Nithsdale Schizophrenia Surveys 23: movement disorders. Br. J. Psychiatry181, 422–427 (2002).
   PubMed Web of Science ®Google Scholar
• Lee PE, Sykora K, Gill SS et al. Antipsychotic medication and drug-induced movement disorder: a population-based cohort study in older adults. J. Am. Geriatr. Soc.53, 1374–1379 (2005).
   PubMed Web of Science ®Google Scholar
• Rochon PA, Stukel TA, Sykora K et al. Atypical antipsychotics and parkinsonism. Arch. Intern. Med.165, 1882–1888 (2005).
   PubMed Web of Science ®Google Scholar
• Kane JM. Commentary on the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). J. Clin. Psychiatry76(5), 831–832 (2006).
   Google Scholar
• Tandon R, Constatine. Avoiding EPS is key to realizing “atypical benefits”. Curr. Psychiatry5(11), 35–45 (2006).
   Google Scholar
• Rosenheck RA, Stroup TS, Keefe RSE, McEvoy J Swartz M, Lieberman JA. Study samples key to assessing risk (letter). Curr. Psychiatry6(1), 3–4 (2007).
   Google Scholar
• Swanson JW, Swartz MS, Van Dorn RA et al. A national study of violent behavior in persons with schizophrenia. Arch. Gen. Psychiatry63, 490–499 (2006).
   PubMed Web of Science ®Google Scholar
• Rosenheck RA, Hoff RA, Steinwachs D, Lehman A. Benchmarking treatment of schizophrenia: a comparison of service delivery by the national government and by state and local providers. J. Nerv. Ment. Dis.188(4), 209–216 (2000).
   PubMed Web of Science ®Google Scholar
• Lehman A. A quality of life interview for the chronically mentally ill. Eval. Program. Plann.11, 51–62 (1988).
   Web of Science ®Google Scholar
• Lieberman JA, Tollefson G, Tohen M et al.; HGDH Study Group. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am. J. Psychiatry160(8), 1396–404 (2003).
   PubMed Web of Science ®Google Scholar
• Schooler N, Rabinowitz J, Davidson M et al. Early Psychosis Global Working Group. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am. J. Psychiatry162(5), 947–953 (2005).
   PubMed Web of Science ®Google Scholar
• Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost Effectiveness in Health and Medicine. Oxford University Press, NY, USA (1996).
   Google Scholar
• Swartz M, Perkins D, Stroup S et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE Study. Am. J. Psychiatry (2007) (In Press).
   Google Scholar
• Keefe RSE, Bilder R, Davis S et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch. Gen. Psychiatry. (2007) (In Press).
   Google Scholar
• Pyne JM, Sullivan G, Kaplan R, Williams DK. Comparing the sensitivity of generic effectiveness measures with symptom improvement in persons with schizophrenia. Med. Care41(2), 208–217 (2003).
   Google Scholar
• Kelsey JL, Whittemore AS, Evans AS, Thompson DS. Methods in Observational Epidemiology (2nd Edition). Oxford University Press, New York, NY, USA (1996).
   Google Scholar
• A Dictionary of Epidemiology (3rd Edition). Last JM (Ed.). Oxford University Press, New York, NY, USA (1996).
   Google Scholar
• Rosenheck RA. Comment on “Tardive dyskinesia circa 2006”. Am. J. Psychiatry164(1), 170 (2007).
   Google Scholar
• Essock SM, Covell NH, Davis SM, Stroup SS, Rosenheck RA, Lieberman JA. Effectiveness of switching antipsychotic medications. Am. J. Psychiatry.163(12), 2090–2095 (2006).
   PubMed Web of Science ®Google Scholar
• Polsky D, Doshi JA, Bauer MS, Glick HA. Clinical trial-based cost–effectiveness analyses of antipsychotic use. Am. J. Psychiatry163(12), 2047–2056 (2006).
   PubMed Web of Science ®Google Scholar
• Rosenheck RA (2005). The growth of psychopharmacology in the 1990s: evidence-based practice or irrational exuberance. Int. J. Law Psychiatry28(5), 467–483 (2005).
   Google Scholar
• Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA289, 454–465 (2003).
   PubMed Web of Science ®Google Scholar
• Jorgensen AW, Hilden J, Gotzsche PC. Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review. Br. Med. J.333(7572), 782 (2006).
   PubMed Web of Science ®Google Scholar
• Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. Br. Med. J.326, 1167–1170 (2003).
   PubMed Web of Science ®Google Scholar